Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
What happened?
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Story details
The round valued the AI biotech at $2 billion.
It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Why it matters
This story helps build a stronger internal English tech archive around Technology, giving search visitors more reasons to keep browsing the site instead of bouncing after a single headline.